These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10840527)

  • 1. Risperidone for control of agitation in dementia patients.
    Falsetti AE
    Am J Health Syst Pharm; 2000 May; 57(9):862-70. PubMed ID: 10840527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
    Zaudig M
    Drug Saf; 2000 Sep; 23(3):183-95. PubMed ID: 11005702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
    Tune LE
    J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol for agitation in dementia.
    Lonergan E; Luxenberg J; Colford J
    Cochrane Database Syst Rev; 2001; (4):CD002852. PubMed ID: 11687166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
    Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.
    Teranishi M; Kurita M; Nishino S; Takeyoshi K; Numata Y; Sato T; Tateno A; Okubo Y
    J Clin Psychopharmacol; 2013 Oct; 33(5):600-7. PubMed ID: 23948783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A structured trial of risperidone for the treatment of agitation in dementia.
    Lavretsky H; Sultzer D
    Am J Geriatr Psychiatry; 1998; 6(2):127-35. PubMed ID: 9581208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of atypical antipsychotics in elderly patients with dementia.
    Tariot PN; Profenno LA; Ismail MS
    J Clin Psychiatry; 2004; 65 Suppl 11():11-5. PubMed ID: 15264966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.
    Bhana N; Spencer CM
    Drugs Aging; 2000 Jun; 16(6):451-71. PubMed ID: 10939309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
    Rabinowitz J; Davidson M; De Deyn PP; Katz I; Brodaty H; Cohen-Mansfield J
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):991-8. PubMed ID: 16286443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H; Slyk MP; Deymann S; Cornacchione MJ
    J Am Med Dir Assoc; 2003; 4(4):183-8. PubMed ID: 12837138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone for AIDS-associated dementia: a case series.
    Belzie LR
    AIDS Patient Care STDS; 1996 Aug; 10(4):246-9. PubMed ID: 11361596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
    Suh GH; Greenspan AJ; Choi SK
    Int J Geriatr Psychiatry; 2006 Jul; 21(7):654-60. PubMed ID: 16821257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
    Freund-Levi Y; Jedenius E; Tysen-Bäckström AC; Lärksäter M; Wahlund LO; Eriksdotter M
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):341-8. PubMed ID: 24035407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
    De Deyn PP; Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():19-22. PubMed ID: 11584983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone for the treatment of neuropsychiatric features in dementia.
    Burns A; De Deyn PP
    Drugs Aging; 2006; 23(11):887-96. PubMed ID: 17109567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.